Patented platform specializes in delivering 100% pure drugs directly to the site of disease

Lawrence, KS— May 19, 2025 — CritiTech Particle Engineering Solutions’ Purcision™ technology was recently nominated for Outsourced Pharma’s 2025 Juried Award for Most Promising Drug Delivery Technology. The nomination is part of Outsourced Pharma’s 14^th annual CDMO Leadership Awards. Juried Award nominations were voted on by a panel of industry professionals across multiple categories “focused on delivering quality results for their customers.” 

“This recognition reflects the passion, innovation and relentless drive of our amazing team,” said Matthew McClorey, President at CritiTech Particle Engineering Solutions. “We are proud to be pushing the boundaries of what’s possible for drug delivery, and we thank Outsourced Pharma, our partners and clients, and everyone who has supported our growth into a leading CDMO.”

Purcision™ Technology Propelling Multiple Drug Candidates Through Clinical Trials

Several drug development projects are advancing through clinical trials with Purcision™-engineered materials including targeted treatments for indications ranging from cancer to asthma and COPD, from autoimmune diseases to exposure to chemical warfare agents. Purcision™ technology’s unique processing allows development of 100% pure drug formulations, free from excipients or additives, with greater potency and controlled duration for release. By focusing Purcision™-engineered drugs at the site of disease with these unique particle characteristics, treatments can be targeted and limit systemic exposure and side effects.

“We have been told by multiple clients that they could not succeed with their drug formulations without Purcision™,” said Michael Baltezor, Chief Technology Officer for CritiTech Particle Engineering Solutions. “To be fair, it doesn’t work with everything. But when it does, the results are extraordinary.”

Experienced, Growing and U.S.-Based CDMO

CritiTech Particle Engineering Solutions provides CDMO services beyond Purcision™ technology including spray drying and jet milling, complemented by comprehensive on-site analytical testing services, robust quality assurance and a growing capability in fill-finish. Offering drug particle engineering from early pre-formulation through clinical formulation and drug production and testing from proof of concept to GMP through to commercial, the company also specializes in working with potent materials and has dedicated cytotoxic and non-cytotoxic facilities. Inhaled formulations have been a particular focus in recent years.

To learn more about the award-nominated Purcision™ technology or the full suite of CDMO services that CritiTech Particle Engineering Solutions, provides, please visit https://crititech.com.

###

For more information, press only:

Jody Schrandt

(785) 330-7833

[email protected]